<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2463">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04821973</url>
  </required_header>
  <id_info>
    <org_study_id>2020-35</org_study_id>
    <secondary_id>2020-A01627-32</secondary_id>
    <nct_id>NCT04821973</nct_id>
  </id_info>
  <brief_title>Respiratory Tele Monitoring COVID 19 (TMR COVID-19)</brief_title>
  <official_title>Interest of Respiratory Tele Monitoring in COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The determinants of the evolution to a severe form for COVID-19 pneumonia remain unclear.&#xD;
      COVID-19 pneumonia is characterized by a hypoxemia with a possible rapid worsening and&#xD;
      related resuscitation requirement. The monitoring of patients in hospital wards (excluding&#xD;
      intensive care unit) is therefore both necessary and complicated given the contagious risks&#xD;
      for health workers.&#xD;
&#xD;
      The COVID 19 Respiratory Tele Monitoring (RTM COVID 19) research project is based on a&#xD;
      comparison between usual nurse respiratory monitoring (4 to 6 time per day) of respiratory&#xD;
      parameters (capillary oxygen saturation, respiratory rate, hearth rate) and a continuous&#xD;
      monitoring of these respiratory parameters with continuous monitoring by a portable, wireless&#xD;
      and stand-alone device.&#xD;
&#xD;
      The main objective of this work is a more sensitive and earlier detection of respiratory&#xD;
      degradation events in patients with COVID-19 pneumonia (capillary desaturation, increased&#xD;
      respiratory rate) requiring the introduction of oxygen therapy, its increase or a&#xD;
      resuscitation requirement with possible intensive care admission.&#xD;
&#xD;
      A prospective, randomized, multicentre, comparative exposure study will be conducted with&#xD;
      planned inclusion of 80 patients. This investigation will focus on patients with COVID-19&#xD;
      pneumonia hospitalized in dedicated medical wards of two University Hospitals in France.&#xD;
&#xD;
      A randomization will be stratified by Hospital and adapted so that each Hospital provides the&#xD;
      same number of subjects in each arms:&#xD;
&#xD;
        -  Control Respiratory Monitoring Group (40 patients)&#xD;
&#xD;
        -  Experimental Respiratory Monitoring Group (40 patients)&#xD;
&#xD;
      The main criterion is respiratory degradation event, during a 4 days period after ward&#xD;
      admission, which motivates a change in the therapeutic strategy defined by the presence of at&#xD;
      least one of these elements:&#xD;
&#xD;
        -  Capillary saturation &lt; 94% (regardless of oxygen intake) for at least 2 minutes.&#xD;
&#xD;
        -  And/or an increase in respiratory rate &gt; 20/minute for at least 2 minutes.&#xD;
&#xD;
      The modification of the therapeutic strategy is defined by:&#xD;
&#xD;
        -  Introduction of oxygen therapy for included patients without oxygen therapy or&#xD;
           supplementation of oxygen therapy &gt; 2 litres/minutes for included patients with oxygen&#xD;
           therapy&#xD;
&#xD;
        -  And/or introduction of a high oxygen concentration mask&#xD;
&#xD;
        -  And/or Request an On-Site Opinion from a member of the resuscitation team.&#xD;
&#xD;
        -  And/or Transfer to intensive care or resuscitation unit&#xD;
&#xD;
        -  And/or Need for immediate resuscitation for life-threatening distress.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2020</start_date>
  <completion_date type="Anticipated">November 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>respiratory degradation event 1</measure>
    <time_frame>during the 4 days period</time_frame>
    <description>Capillary saturation &lt; 94% (regardless of oxygen intake) for at least 2 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>respiratory degradation event 2</measure>
    <time_frame>during the 4 days period</time_frame>
    <description>an increase in respiratory rate &gt; 20/minute for at least 2 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New Early Warning Score (NEWS) evaluation</measure>
    <time_frame>during the 4 days period</time_frame>
    <description>post hoc comparison of the respiratory monitoring using the experimental device with the NEWS on the repiratory event occurence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of caregiver feelings</measure>
    <time_frame>during the 4 days period</time_frame>
    <description>post hoc analysis of the team in regard to the monitoring strategy used based on a self-assessment questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit tansfer</measure>
    <time_frame>during the 4 days period</time_frame>
    <description>post hoc analysis of the frequency of ICU transfer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Control Respiratory Monitoring Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Respiratory Monitoring Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radius PPG Tetherless Pulse Oximetry (Masimo)</intervention_name>
    <description>continuous monitoring by a portable, wireless and stand-alone device</description>
    <arm_group_label>Experimental Respiratory Monitoring Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>usual monitoring</intervention_name>
    <description>usual nurse respiratory monitoring</description>
    <arm_group_label>Control Respiratory Monitoring Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with COVID 19 pneumonia assessed by PCR and CT scann.&#xD;
&#xD;
          -  Patient admited in a dedicated medical ward&#xD;
&#xD;
          -  Patient with oxygen supply less or equal to 4 liters per minute.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with limitation of care.&#xD;
&#xD;
          -  Patient with immediate risk to ICU transfer within the first 12 hours&#xD;
&#xD;
          -  Patient with neurological or psychiatric symptoms that interfere with respiratory&#xD;
             parameters interpretation.&#xD;
&#xD;
          -  Patient with acute or chronic respiratory disease such as COPD, cancer.&#xD;
&#xD;
          -  Pregnancy, age &lt; 18 of vulnerable profile.&#xD;
&#xD;
          -  Patient refusal to participate or previously included in a clinical research trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GARRIDO-PRADALIE Emilie</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre MICHELET</last_name>
    <phone>04 13 42 97 05</phone>
    <phone_ext>+33</phone_ext>
    <email>pierre.michelet@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claire MORANDO</last_name>
    <phone>0491382183</phone>
    <phone_ext>+33</phone_ext>
    <email>claire.morando@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre MICHELET</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

